Skip to main content

 

RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)

This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".

A Brief History of Rheumatoid Arthritis Mimics

Imagine that 100 years from now, your great granddaughter, an eminent rheumatologist, reviews the history of rheumatoid arthritis (RA) mimics.

Hard Decisions in RA (9.1.2023)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Mono- and Oligo- are Different (8.18.2023)

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.

English for the Biologically-Challenged (8.4.2023)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.

"Ask Cush Anything" Returns (7.21.2023)

Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything"

Danger with Hydroxychloroquine Nonadherence in SLE

A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality.

Anti-Drug Antibodies with Biologics (7.14.2023)

Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!

ICYMI: Hydroxychloroquine Dose and Risk for Incident Retinopathy

Editor's note: This article originally appeared January 18, 2023 and is being shared again this week in case you missed it. 

ICYMI: 25 Great Women in Rheumatology

Editor's note: This article originally appeared April 26, 2023, and is being shared again this week in case you missed it. 

What is Colchicine Worth? (6.23.2023)

Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?

EULAR 2023 Notes from Milan (6.09.2023)

Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.

Lupus

Social

This poster makes me happy for so many reasons 😆 Aggressive & descriptive title? ☑️ Pretty chloropleth map? ☑️ Dunks on hamfisted EMR tools trying to replace patient-physician interactions? ☑️ @RheumNow #ACR24 Abstr#0668 ThereAreNoShortcuts https://t.co/IXYaHAi15q
Mike Putman @EBRheum ( View Tweet )
1 year 1 month ago
This is likely an oversimplification, but I've been looking for exactly this diagram Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition @EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No? @rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3
Mike Putman @EBRheum ( View Tweet )
1 year 1 month ago
Cardiology 🤝 Rheumatology #Abstract0611 highlights Subclinical atherosclerosis (carotid plaque > 1.5 mm) associated with ↑ risk of CV events in SLE longitudinal cohort @RheumNow #ACR24 https://t.co/jLLYNOfFZ2
Akhil Sood MD @AkhilSoodMD ( View Tweet )
1 year 1 month ago
Which lupus nephritis patients are at higher risk for CKD? #Abstract0624 shows coexisting tubulointerstitial inflammation/damage (TII/TID) on renal biopsy is linked to CKD progression (HR 2.667, 95% CI: 1.333-5.335) Risk high among Class III, IV, V and eGFR > 30 @RheumNow #ACR24

Akhil Sood MD @AkhilSoodMD ( View Tweet )

1 year 1 month ago
Mycophenolate isn't great for vaccine immunogenicity, but withholding MMF for one week after both doses of recombinant zoster vaccine boosts Ab titres ++ in this Brazilian RCT. A week off post-vaccine: definitely worth considering in stable disease #ACR24 ABST0247 @RheumNow https://t.co/lajS5DzRbD
David Liew @drdavidliew ( View Tweet )
1 year 1 month ago
CKD keeps a persistent low grade inflammatory state! Implications: CKD ⬆️risk for CV dz through different mech @RheumNow #ACR24 https://t.co/KcCvyTVaav
TheDaoIndex @KDAO2011 ( View Tweet )
1 year 1 month ago
#ACR24 Ab#0771 ARID5B - transcription factor controls pathologic inflammatory fibroblast ARID5B: RA risk locus on GWAS, also link to SLE, Graves Binds to histone editors to epigenetically regulate fibroblast state ARID5B deletion incr inflamm response, overexpr decr @RheumNow https://t.co/ebKnX1uTuO
1 year 1 month ago
Save the date! RheumNow will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/rDMFH3wlbc
Dr. John Cush @RheumNow ( View Tweet )
1 year 1 month ago
Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/uKc14y1fOm
Dr. John Cush @RheumNow ( View Tweet )
1 year 1 month ago
Hydroxychloroquine effects studied in 30pts (23 RA, 7SLE). Results did not support that HCQ may reduce CV risk - Arterial stiffness was not affected by HCQ, HCQ modestly lowered HbA1c & lipids - yet HCQ has been shown to reduced CV risk in observational studies… https://t.co/n283HwvRm4 https://t.co/lQN342uevy
Dr. John Cush @RheumNow ( View Tweet )
1 year 1 month ago
×